New CAR-T therapy aims to tackle tough childhood leukemia

NCT ID NCT07244406

Recruiting now Disease control Sponsor: Hebei Senlang Biotechnology Inc., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cells. The main goal is to see how many patients achieve remission three months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Senl_B19 autologous anti-CD19 CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for children and young adults with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong: This is a phase 2 trial with only 59 participants, so results are still early. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-ALL

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.